Drug Profile


Alternative Names: EVIZON; MSI-1256F; OHR 102; Squalamine lactate

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genaera Corporation
  • Developer Genaera Corporation; Ohr Pharmaceutical
  • Class Antineoplastics; Cholestanols; Eye disorder therapies; Lactates; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factor C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase II Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion
  • Discontinued Fibrodysplasia ossificans progressiva; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 25 Apr 2017 Ohr Pharmaceutical withdraws a phase II trial prior to enrolment due to a company decision in Wet age-related macular degeneration (Combination therapy, In adults, In the elderly) in USA (Ophthalmic) (NCT02511613)
  • 14 Feb 2017 Ohr Pharmaceutical suspended enrolment in the phase III trial for Wet age-related macular degeneration
  • 22 Dec 2016 Updated efficacy data from the phase II IMPACT trial in Wet age-related macular degeneration released by Ohr Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top